- Supported exchanges /
- F /
- 328.F
MEIRAGTX HLDGSDL-0000388 (328 F) stock market data APIs
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.
MEIRAGTX HLDGSDL-0000388 Financial Data Overview
| 5.4 | |
| 5.35 | |
| - | |
| 5.4 | |
| 5.35 | |
| 3.4-6.6 | |
| 414 M | |
| 77 184 K | |
| 8 122 K | |
| -0.46 | |
| 1.291 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
MEIRAGTX HLDGSDL-0000388 Fundamental Data is available in our Financial Data APIs
- Net Revenue 8 122 K
- EBITDA -155 308 992
- Earnings Per Share -1.32
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get MEIRAGTX HLDGSDL-0000388 Earnings via APIs
- Latest Release 2021-06-30
- EPS/Forecast -0.54
Get MEIRAGTX HLDGSDL-0000388 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
